These emerging treatments, Retatrutide, represent a significant advancement in treating obesity and possibly associated conditions . These drugs are classified as GLP-1 hormone agonists , indicating https://finniandwds964148.p2blogs.com/39901717/semaglutide-a-deep-dive-into-incretin-copyright